Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 406 Carcinoma, Non-Small-Cell Lung 147 Urinary Bladder Neoplasms 87 Breast Neoplasms 84 Cholangiocarcinoma 83 Lung Neoplasms 78 Neoplasm Metastasis 67 Neoplasms 64 Biliary Tract Neoplasms 58 Nasopharyngeal Carcinoma 53 Ovarian Neoplasms 46 Sarcoma 43 Recurrence 39 Gallbladder Neoplasms 39 Hodgkin Disease 34 Lymphoma, Large B-Cell, Diffuse 33 Lymphoma 32 Carcinoma, Transitional Cell 29 Bile Duct Neoplasms 24 Adenocarcinoma 23 Fallopian Tube Neoplasms 19 Carcinoma, Hepatocellular 19 Adenocarcinoma of Lung 18 Triple Negative Breast Neoplasms 17 Lymphoma, Non-Hodgkin 17 Liver Neoplasms 17 Nasopharyngeal Neoplasms 16 Lymphoma, Extranodal NK-T-Cell 16 Carcinoma 16 Non-Muscle Invasive Bladder Neoplasms 15

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Gemcitabine × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡